Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Kelner

Pain Medicine Las Vegas, NV Medical Doctor

NPI 1578976965 CMS profile 436719

1569 E Flamingo Rd, Las Vegas, NV 89119

Open in the dashboard

General payments

$4,029

32 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Kelner of Las Vegas, NV is reported in the CMS Open Payments database as having received $4,029 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $138 3
2022 General $1,918 12
2020 General $322 4
2019 General $1,633 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Kelner
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Andrew Kelner were reported at $19. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Andrew Kelner Pain Medicine median Middle half National median
2019 $1,633 $498 $126–$1,682 $163
2020 $322 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $1,918 $455 $137–$1,484 $149
2023 $0 $484 $128–$1,495 $160
2024 $138 $498 $131–$1,540 $164
2025 $19 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,111 16 payments
  2. Nevro Corp. $1,633 12 payments
  3. Boston Scientific Corporation $153 1 payment
  4. Curonix LLC $132 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,475 8 payments
  2. Food and Beverage $1,553 24 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $1,837 7 payments
  2. Senza Spinal Cord Stimulation System $1,633 12 payments
  3. Proclaim Family of SCS IPGs $169 3 payments
  4. SUPERION $153 1 payment
  5. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $132 3 payments
  6. EXCLAIM $60 4 payments
  7. PROCLAIM Neuromodulation $24 1 payment
  8. PROCLAIM Neuromodulation $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,545

Median for Pain Management: 951

Drug cost

$42,007

Median for Pain Management: $26,034

Branded share of claims

48.2%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 42 $9,488
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 402 $8,238
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 223 $7,235
Lidocaine Generic 28 $5,771
Gabapentin Generic 141 $1,720
Oxycodone Hcl Generic 78 $1,410
Morphine Sulfate Er Morphine Sulfate Brand 45 $1,349
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 11 $1,139
Tizanidine Hcl Generic 115 $963
Pregabalin Generic 38 $612

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$65,922

Of which drugs: $11

Medicare patients

200

Average age 70

Services billed

921

129 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 35%
Diabetes 32%
COPD 25%
Chronic kidney disease 24%
Ischemic heart disease 23%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 126 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record